Related Experiment Video

Updated: Jun 20, 2026

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin
11:17

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

Beta2-microglobulin

Tilman B Drüeke1, Ziad A Massy

  • 1Inserm Unit 845, Necker Medical School, University Paris-Descartes, Paris, France. tilman.drueke@inserm.fr

Seminars in Dialysis
|August 28, 2009
PubMed

Insights

Beta2-microglobulin (beta2-M) is a key uremic toxin that accumulates in chronic kidney disease. While dialysis removes beta2-M, predialysis levels remain high, contributing to amyloidosis.

Area of Science:

  • Nephrology
  • Biochemistry
  • Internal Medicine

Background:

  • Beta2-microglobulin (beta2-M) is a middle molecule uremic toxin.
  • Serum beta2-M levels rise with chronic kidney disease progression, especially in end-stage renal disease.
  • High extracellular beta2-M contributes to dialysis-related amyloidosis.

Purpose of the Study:

  • To review the role of beta2-M in kidney disease.
  • To discuss the implications of beta2-M accumulation and removal.
  • To examine trends in beta2-M amyloidosis.

Main Methods:

  • Literature review on beta2-M in chronic kidney disease.
  • Analysis of beta2-M's role in dialysis-related amyloidosis.
  • Discussion of hemodialysis and hemodiafiltration efficacy.

Main Results:

  • Beta2-M is a significant uremic toxin and a major component of dialysis-related amyloidosis.
  • Effective dialysis techniques reduce beta2-M, but predialysis levels persist.
  • The incidence of beta2-M amyloidosis may be decreasing or delayed.

Conclusions:

  • Beta2-M accumulation is a critical factor in dialysis-related amyloidosis.
  • Current dialysis methods improve but do not normalize predialysis beta2-M levels.
  • Long-term trends suggest a potential shift in the timing or prevalence of beta2-M amyloidosis.

More Related Videos

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins10:05

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Published on: August 7, 2014

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry09:38

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry

Published on: June 26, 2019

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...